(Press-News.org) European legislation restricts animal testing within the pharmaceutical and cosmetic industries and companies are increasingly looking at alternative systems to ensure that their products are safe to use. Research published in BioMed Central's open access journal BMC Genomics demonstrates that the response of laboratory grown human cells can now be used to classify chemicals as sensitizing, or non-sensitizing, and can even predict the strength of allergic response, so providing an alternative to animal testing.
Allergic contact dermatitis can result in itching and eczema and is often due to repeated exposure to chemicals at work or in everyday life such as machine oil, detergents, soaps, and cosmetics. Unless the source of the sensitizing chemical is found the resulting rashes can be an ongoing source of misery for the sufferer. The 2009, 7th Amendment to the Cosmetic Directive bans testing of cosmetic products and ingredients on animals meaning that there is currently no way of ensuring new products are hypoallergenic.
Researchers from Lund University in Sweden used genome-wide profiling to measure the response of a human myeloid leukemia cell line to known chemicals. From this they defined a 'biomarker signature' of 200 genes, which could accurately discriminate between sensitizing and non-sensitizing chemicals. By comparing this signature with the known action of these chemicals they were also able to use this system to predict sensitizing potency.
Prof Borrebaeck said, "REACH (Registration, Evaluation, and Authorization of Chemicals) regulation requires that all new and existing chemicals within the European Union are tested for safety. The number of chemicals this includes is over 30,000 and is increasing all the time. Our lab-based alternative to animal testing, although in an early stage of production, is faster, out-performs present alternatives, and, because the cells are human in origin, is more relevant. It provides a way of ensuring the continued safety of consumers and users and, by identifying chemicals and products with low immunogenicity, reducing the suffering due to eczema."
###
Media Contact
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: +44 (0) 20 3192 2370
Email: hilary.glover@biomedcentral.com
Notes to Editors
1. A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests
Henrik Johansson, Malin Lindstedt, Ann-Sofie Albrekt and Carl AK Borrebaeck
BMC Genomics, (in press)
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at press@biomedcentral.com on the day of publication.
2. BMC Genomics - is an Open Access, peer-reviewed journal that considers articles on all aspects of genome-scale analysis, functional genomics, and proteomics.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector
Cell-based alternative to animal testing
2011-08-09
ELSE PRESS RELEASES FROM THIS DATE:
Research discovers frequent mutations of chromatin remodeling genes in TCC of the bladder
2011-08-09
August 8th, 2011, Shenzhen, China – BGI, the world's largest genomics organization, Peking University Shenzhen Hospital and Shenzhen Second People's Hospital, announced today that the study on frequent mutations of chromatin remodeling genes in transitional cell carcinoma (TCC) of the bladder was published online in Nature Genetics. This study provides a valuable genetic basis for future studies on TCC, suggesting that aberration of chromatin regulation might be one of the features of bladder cancer.
Bladder cancer is the ninth most common type of cancer worldwide, which ...
How yeast chromosomes avoid the bad breaks
2011-08-09
CAMBRIDGE, Mass. (August 7, 2011) – The human genome is peppered with repeated DNA elements that can vary from a few to thousands of consecutive copies of the same sequence. During meiosis—the cell division that produces sperm and eggs—repetitive elements place the genome at risk for dangerous rearrangements from genome reshuffling. This recombination typically does not occur in repetitive DNA, in part because much of it is assembled into specialized heterochromatin. Other mechanisms that restrain recombination in repetitive DNA have remained elusive, until now.
In a ...
Researchers gain new insights into how tumor cells are fed
2011-08-09
Philadelphia, PA, August 8, 2011 – Researchers have gained a new understanding of the way in which growing tumors are fed and how this growth can be slowed via angiogenesis inhibitors that eliminate the blood supply to tumors. This represents a step forward towards developing new anti-cancer drug therapies. The results of this study have been published today in the September issue of The American Journal of Pathology.
"The central role of capillary sprouting in tumor vascularization makes it an attractive target for anticancer therapy. Our observations suggest, however, ...
Genetic analysis of amniotic fluid shows promise for monitoring fetal development
2011-08-09
Philadelphia, PA, August 8, 2011 – Researchers have demonstrated the feasibility of focused fetal gene expression analysis of target genes found in amniotic fluid using Standardized NanoArray PCR (SNAP) technology. This analysis could be used to monitor fetal development, enabling clinicians to determine very early in pregnancy whether fetal organ systems are developing normally. The study appears today in the September issue of The Journal of Molecular Diagnostics.
Using a previously developed SNAP gene panel as proof of concept, investigators from the Floating Hospital ...
Early morning smokers have increased risk of lung and head and neck cancers
2011-08-09
Two new studies have found that smokers who tend to take their first cigarette soon after they wake up in the morning may have a higher risk of developing lung and head and neck cancers than smokers who refrain from lighting up right away. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the results may help identify smokers who have an especially high risk of developing cancer and would benefit from targeted smoking interventions to reduce their risk.
Cigarette smoking increases one's likelihood of developing various types of ...
Technique to stimulate heart cells may lead to light-controlled pacemakers
2011-08-09
A new technique that stimulates heart muscle cells with low-energy light raises the possibility of a future light-controlled pacemaker, researchers reported in Circulation: Arrhythmia & Electrophysiology, a journal of the American Heart Association.
"Electronic cardiac pacemakers and defibrillators are well established and successful technologies, but they are not without problems, including the breakage of metal leads, limited battery life and interference from strong magnetic fields," said Emilia Entcheva, Ph.D., senior author of the study and associate professor of ...
Siblings of those with blood clots in leg have higher risk of same disorder
2011-08-09
Siblings of those who have been hospitalized with potentially lethal blood clots in the legs or pelvis are more likely to also suffer the disorder than those with healthy siblings, according to research published in Circulation: Journal of the American Heart Association.
The Swedish study is the first to show a direct correlation between venous thromboembolism (VTE) and family risk in a nationwide setting, sorted by age and gender.
VTE consists of deep vein thrombosis (DVT), which typically involves blood clots that form in the deep veins of the leg or pelvis, and ...
Light speed hurdle to invisibility cloak overcome by undergraduate
2011-08-09
An undergraduate student has overcome a major hurdle in the development of invisibility cloaks by adding an optical device into their design that not only remains invisible itself, but also has the ability to slow down light.
The optical device, known as an 'invisible sphere', would slow down all of the light that approaches a potential cloak, meaning that the light rays would not need to be accelerated around the cloaked objects at great speeds ― a requirement that has limited invisibility cloaks to work only in a specified region of the visible spectrum.
This ...
Drug development in the blink of an eye
2011-08-09
The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects. But now, Jeremy Nathans and colleagues, at Johns Hopkins University School of Medicine, Baltimore, have developed a new preclinical approach that they hope can be used alongside current strategies to guide more efficient drug development for brain-related conditions.
In the study, ...
JCI online early table of contents: August 8, 2011
2011-08-09
EDITOR'S PICK: Drug development in the blink of an eye
The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects. But now, Jeremy Nathans and colleagues, at Johns Hopkins University School of Medicine, Baltimore, have developed a new preclinical approach that they hope can be used alongside current strategies to guide more efficient ...